Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.68 |
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | F10 | P00742 | 15/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | CALML3 | P27482 | 1/20 | 0.55 |
| ▸ | SDHA | P31040 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151739 | 0.91 | MAOB (0.66) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL3150267 | 0.91 | F10 (0.69) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL6674415 | 0.86 | F10 (0.62) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL3151481 | 0.83 | F10 (0.57) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL5216684 | 0.82 | MAOB (0.84) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL3151580 | 0.82 | F10 (0.67) | MAOBMAOAF10LMNAPTGS1 | |
| Sutezolid SCHEMBL2152517 | 0.82 | MAOB (1.00) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL6160301 | 0.82 | MAOB (0.85) | MAOBMAOAF10LMNAPTGS1 | |
| Sutezolid SCHEMBL29757643 | 0.82 | MAOB (1.00) | MAOBMAOAF10LMNAPTGS1 | |
| SCHEMBL6040542 | 0.82 | MAOB (0.85) | MAOBMAOAF10LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1526132-B1 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | BAYER IP GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| EP-1411932-B1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER SCHERING PHARMA AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| EP-1937271-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | Bayer HealthCare AG (DE) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042146-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG (DE) | 2007-04-19 | — | — | WO | disclosed |
| EP-1526132-A2 | Substituted oxazolidinone derivatives and their use as factor xa inhibitors | Bayer HealthCare AG (DE) | 2005-04-27 | — | — | EP | disclosed |
| EP-1261606-B1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER HEALTHCARE AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| EP-1411932-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003000256-A9 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER AG (DE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2003000256-A1 | SUBSTITUTED OXAZOLIDINONES FOR COMBINATIONAL THERAPY | BAYER HEALTHCARE AG (DE) | 2003-01-03 | — | — | WO | disclosed |
| WO-2001047919-A9 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER AG (DE) | 2002-12-19 | — | — | WO | disclosed |